PENTOXIL (pentoxifylline) by ANI Pharmaceuticals is clinical pharmacology mode of action: pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. First approved in 1999.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Mode of Action: Pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. In patients with chronic peripheral arterial disease, this increases blood flow to the affected microcirculation and enhances tissue oxygenation. The precise…
Worked on PENTOXIL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
Bioequivalence Study of Pentoxifylline 400 Mg in Healthy Subjects Under Fasting and Fed Conditions
PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients
Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)